(NYSE:SOC), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Sable Offshore Corp. (“Sable” or the “Company”) (NYSE: SOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sable and certain of its officers and/or directors have […]
(NASDAQ:SATS), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of EchoStar Corporation (“EchoStar” or the “Company”) (NASDAQ: SATS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether EchoStar and certain of its officers and/or directors have engaged
(NASDAQ:GILD), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Gilead and certain of its officers and/or directors have
(NASDAQ:QIPT), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Quipt and certain of its officers and/or directors
(NYSE:BF-A),(NYSE:BF-B), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Brown-Forman Corporation (“Brown-Forman” or the “Company”) (NYSE: BF-B; BF-A). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Brown-Forman and certain of its officers and/or directors have
(NASDAQ:GRPN), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Groupon, Inc. (“Groupon” or the “Company”) (NASDAQ: GRPN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Groupon and certain of its officers and/or directors have engaged
(NASDAQ:TSLA), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Tesla, Inc. (“Tesla” or the “Company”) (NASDAQ: TSLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Tesla and certain of its officers and/or directors have engaged
(NASDAQ:ARGX), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors have engaged
(NYSE:KBR), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether KBR and certain of its officers and/or directors have engaged
(NasdaqGM:ALT), NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged